Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Martin A. Walter
Based on 4 articles published since 2010
(Why 4 articles?)

Between 2010 and 2020, Martin A. Walter wrote the following 4 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Article Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis. 2019

Kaderli, Reto M / Spanjol, Marko / Kollár, Attila / Bütikofer, Lukas / Gloy, Viktoria / Dumont, Rebecca A / Seiler, Christian A / Christ, Emanuel R / Radojewski, Piotr / Briel, Matthias / Walter, Martin A. ·Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland. · Department of Nuclear Medicine, University Hospital, University of Geneva, Geneva, Switzerland. · Department of Medical Oncology, Bern University Hospital, University of Bern, Bern, Switzerland. · Clinical Trials Unit Bern, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. · Department of Endocrinology, Diabetes, and Metabolism, Basel University Hospital, University of Basel, Basel, Switzerland. · Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, Basel University Hospital, University of Basel, Basel, Switzerland. · Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. ·JAMA Oncol · Pubmed #30763436.

ABSTRACT: Importance: Multiple therapies are currently available for patients with neuroendocrine tumors (NETs), yet many therapies have not been compared head-to-head within randomized clinical trials (RCTs). Objective: To assess the relative safety and efficacy of therapies for NETs. Data Sources: PubMed, Embase, the Cochrane Central Register of Controlled Trials, trial registries, meeting abstracts, and reference lists from January 1, 1947, to March 2, 2018, were searched. Key search terms included neuroendocrine tumors, gastrointestinal neoplasms, therapy, and randomized controlled trial. Study Selection: Randomized clinical trials comparing 2 or more therapies in patients with NETs (primarily gastrointestinal and pancreatic) were evaluated. Thirty RCTs met the selection criteria. Data Extraction and Synthesis: Pairs of independent reviewers screened studies, extracted data, and assessed the risk of bias. A network meta-analysis with a frequentist approach was used to compare the efficacy of therapies; the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline was used. Main Outcomes and Measures: Disease control, progression-free survival, overall survival, adverse events, and quality of life. Results: The systematic review identified 30 relevant RCTs comprising 3895 patients (48.4% women) assigned to 22 different therapies for NETs. These therapies showed a broad range of risk for serious and nonserious adverse events. The network meta-analyses included 16 RCTs with predominantly a low risk of bias; nevertheless, precision-of-treatment estimates and estimated heterogeneity were limited. The network meta-analysis found 7 therapies for pancreatic NETs: everolimus (hazard ratio [HR], 0.35 [95% CI, 0.28-0.45]), everolimus plus somatostatin analogue (HR, 0.35 [95% CI, 0.25-0.51]), everolimus plus bevacizumab plus somatostatin analogue (HR, 0.44 [95% CI, 0.26-0.75]), interferon (HR, 0.37 [95% CI, 0.16-0.83]), interferon plus somatostatin analogue (HR, 0.31 [95% CI, 0.13-0.71]), somatostatin analogue (HR, 0.46 [95% CI, 0.33-0.66]), and sunitinib (HR, 0.42 [95% CI, 0.26-0.67]), and 5 therapies for gastrointestinal NETs: bevacizumab plus somatostatin analogue (HR, 0.22 [95% CI, 0.05-0.99]), everolimus plus somatostatin analogue (HR, 0.31 [95% CI, 0.11-0.90]), interferon plus somatostatin analogue (HR, 0.27 [95% CI, 0.07-0.96]), Lu 177-dotatate plus somatostatin analogue (HR, 0.08 [95% CI, 0.03-0.26], and somatostatin analogues (HR, 0.40 [95% CI, 0.21-0.78]) with higher efficacy than placebo and suggests an overall superiority of combination therapies. Conclusions and Relevance: The findings from this study suggest that a range of efficient therapies with different safety profiles is available for patients with NETs.

2 Article Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. 2019

Carlsen, Esben Andreas / Fazio, Nicola / Granberg, Dan / Grozinsky-Glasberg, Simona / Ahmadzadehfar, Hojjat / Grana, Chiara Maria / Zandee, Wouter T / Cwikla, Jaroslaw / Walter, Martin A / Oturai, Peter Sandor / Rinke, Anja / Weaver, Andrew / Frilling, Andrea / Gritti, Sara / Arveschoug, Anne Kirstine / Meirovitz, Amichay / Knigge, Ulrich / Sorbye, Halfdan. ·Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, Denmark. · Department of Biomedical Sciences, Cluster for Molecular Imaging, University of Copenhagen, Copenhagen, Denmark. · Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy. · Department of Medical Sciences, Uppsala University, Uppsala, Sweden. · Neuroendocrine Tumor Unit, Department of Endocrinology & Metabolism, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. · Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. · Division of Nuclear Medicine, IEO, European Institute of Oncology IRCCS, Milan, Italy. · Erasmus Medical Center, Rotterdam, The Netherlands. · Medical School, University of Warmia and Mazury, Olsztyn, Poland. · Department of Nuclear Medicine, University Hospital of Geneva, Geneva, Switzerland. · Department of Gastroenterology, University Hospital Gießen and Marburg, Marburg, Germany. · Department of Oncology, Churchill Hospital, Oxford, UK. · Department of Surgery and Cancer, Imperial College London, London, UK. · Department of Nuclear Medicine and PET, Aarhus University Hospital, Aarhus, Denmark. · Department of Oncology and Radiation Therapy Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. · Departments of Surgical Gastroenterology and Clinical Endocrinology, Rigshospitalet, Copenhagen, Denmark. · Department of Oncology, Haukeland University Hospital, Bergen, Norway. · Department of Clinical Science, University of Bergen, Bergen, Norway. ·Endocr Relat Cancer · Pubmed #30540557.

ABSTRACT: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine tumors grade 1-2 (G1-G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN G3) is largely unknown. We therefore aimed to assess the benefits and side effects of PRRT in patients with GEP NEN G3. We performed a retrospective cohort study at 12 centers to assess the efficacy and toxicity of PRRT in patients with GEP NEN G3. Outcomes were response rate, disease control rate, progression-free survival (PFS), overall survival (OS) and toxicity. We included 149 patients (primary tumor: pancreatic n = 89, gastrointestinal n = 34, unknown n = 26). PRRT was first-line (n = 30), second-line (n = 62) or later-line treatment (n = 57). Of 114 patients evaluated, 1% had complete response, 41% partial response, 38% stable disease and 20% progressive disease. Of 104 patients with documented progressive disease before PRRT, disease control rate was 69%. The total cohort had median PFS of 14 months and OS of 29 months. Ki-67 21-54% (n = 125) vs Ki-67 ≥55% (n = 23): PFS 16 vs 6 months (P < 0.001) and OS 31 vs 9 months (P < 0.001). Well (n = 60) vs poorly differentiated NEN (n = 62): PFS 19 vs 8 months (P < 0.001) and OS 44 vs 19 months (P < 0.001). Grade 3-4 hematological or renal toxicity occurred in 17% of patients. This large multicenter cohort of patients with GEP NEN G3 treated with PRRT demonstrates promising response rates, disease control rates, PFS and OS as well as toxicity in patients with mainly progressive disease. Based on these results, PRRT may be considered for patients with GEP NEN G3.

3 Article The prognostic and predictive value of sstr 2017

Brunner, Philippe / Jörg, Ann-Catherine / Glatz, Katharina / Bubendorf, Lukas / Radojewski, Piotr / Umlauft, Maria / Marincek, Nicolas / Spanjol, Petar-Marko / Krause, Thomas / Dumont, Rebecca A / Maecke, Helmut R / Müller-Brand, Jan / Briel, Matthias / Schmitt, Anja / Perren, Aurel / Walter, Martin A. ·Institute of Pathology, University Hospital Basel, CH, Basel, Switzerland. · Institute of Nuclear Medicine, University Hospital Basel, CH, Basel, Switzerland. · Institute of Nuclear Medicine, University Hospital Bern, CH, 3010, Bern, Switzerland. · Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland. · Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, CH, Switzerland. · Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada. · Institute of Pathology, University Bern, Bern, Switzerland. · Institute of Nuclear Medicine, University Hospital Bern, CH, 3010, Bern, Switzerland. m.a.walter@gmx.net. ·Eur J Nucl Med Mol Imaging · Pubmed #27539020.

ABSTRACT: PURPOSE: Our aim was to assess the prognostic and predictive value of somatostatin receptor 2 (sstr METHODS: We established a tissue microarray and imaging database from NET patients that received sstr RESULTS: We included a total of 279 patients. In these patients, sstr CONCLUSIONS: Our results suggest sstr

4 Article Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. 2011

Grozinsky-Glasberg, Simona / Barak, Dganit / Fraenkel, Merav / Walter, Martin A / Müeller-Brand, Jan / Eckstein, Joseph / Applebaum, Liat / Shimon, Ilan / Gross, David J. ·Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Tel Aviv, Israel. simonag@clalit.org.il ·Cancer · Pubmed #21425137.

ABSTRACT: BACKGROUND: Gastrinomas, a rare group of neuroendocrine tumors, are responsible for severe peptic disease and diarrhea. Although symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs), data are limited regarding the possible antitumor effect of the peptide receptor radioligand therapy (PRRT) with radiolabeled SSAs in gastrinoma patients. The goal of this study was to assess the effect of PRRT on symptoms, gastrin secretion, and tumor load in patients with progressive malignant gastrinomas. METHODS: We retrospectively studied 11 patients with metastatic gastrinomas followed for a mean period of 6 years. All patients were symptomatically treated with PPIs, and 9 of 11 patients received monthly injections of SSAs; all patients had an Eastern Cooperative Oncology Group score of 0-1, and received PRRT ((90) Yttrium- or (177) Lutetium-DOTATOC) for progressive disease. Serum gastrin measurements and radiological assessment (using the Response Evaluation Criteria in Solid Tumors criteria) were performed before and every 3-6 months following PRRT. RESULTS: PRRT induced symptomatic improvement in all patients. The mean serum gastrin decreased significantly from 4831 mI/L to 932.6 mI/L (normal, 40-108 mI/L; P < .001). Periodic radiological surveillance showed complete response in 1 (9%) patient, partial tumor response in 5/11 (45%) patients, and tumor stabilization in 5/11 (45%) patients. In 7/11 (64%) patients, the antitumor effect of PRRT persisted after a median period of 14 months. Four of 11 (36%) patients died due to tumor progression (median time to progression, 11 months); in this group, the mean survival time after the last PRRT was 14 ± 6.9 months. CONCLUSIONS: PRRT seems to be a promising tool for the management of patients with inoperable or progressive metastatic gastrinomas.